Leydig Cell Steroidogenesis & the Rate-Limiting Step
StAR protein and CYP11A1, where testosterone synthesis begins
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (physiology)
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about leydig cell steroidogenesis & the rate-limiting step in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
About 95% of a man's testosterone is made in the Leydig cells of the testes. The pathway starts with cholesterol, and the rate-limiting step is not an enzyme reaction but a transport event: the Steroidogenic Acute Regulatory protein (StAR) ferries cholesterol from the outer to the inner mitochondrial membrane. There, the enzyme CYP11A1 (cholesterol side-chain cleavage) converts it to pregnenolone, the first committed steroid. Luteinizing hormone (LH) drives this whole process by raising cAMP, which acutely upregulates StAR. This is why LH signaling, not raw cholesterol availability, usually governs output.
All testosterone starts with one bottleneck: moving cholesterol into the mitochondrion.
What it is invoked to explain
Claims this idea is used to support. Whether it supports them is the rest of the entry.
How it works
LH binds Leydig-cell receptors, raising cAMP and activating PKA, which rapidly induces StAR to shuttle cholesterol into the mitochondrion. CYP11A1 then cleaves the cholesterol side chain to make pregnenolone, the precursor for all downstream androgens. Because StAR transport is the bottleneck, acute testosterone production is governed by LH-driven StAR activity rather than substrate (cholesterol) supply in most men.
What people get wrong
Often saidEating more cholesterol makes more testosterone
ActuallyCholesterol is the substrate, but the rate-limiting step is StAR-mediated transport driven by LH, not cholesterol availability. Only at very low dietary fat (limiting precursor) does substrate become limiting.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Site
- Leydig cells (testes, ~95% of T)
- Rate-limiting step
- StAR-mediated cholesterol transport
- First enzyme
- CYP11A1 (side-chain cleavage)
- Trigger
- LH -> cAMP -> StAR
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Leydig Cell Steroidogenesis & the Rate-Limiting Step. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
StAR as the rate-limiting regulator,
Classic steroidogenesis research established StAR-mediated cholesterol import as the acute regulatory step, downstream of LH/cAMP signaling